How big pharma keeps drug prices high (with Priti Krishtel and John Arnold)

Episode Summary

Executive Summary: The episode argues that U.S. prescription drug prices are driven not just by high health-care costs but by a broken patent and pricing system that lets pharmaceutical firms extend monopolies far beyond the intended 20 years. Guests Prithi Krishthal and John Arnold explain how patent walls, pay-for-delay deals, PBM distortions, and weak oversight keep prices high, while proposing reforms to restore competition and align drug pricing with social value.

Main Topics: Patent walls and prolonged monopolies (Priority: 5/5): Prithi Krishthal explains how companies file dozens or hundreds of patents on a single drug to extend exclusivity from the statutory 20 years to nearly 40 years or more, preventing generic competition and keeping prices high. Drug pricing as a market failure (Priority: 5/5): The hosts and guests frame prescription drugs as a deeply distorted market where consumers, insurers, and public programs all pay inflated prices for the same medicines compared with peer countries. Pharma industry tactics and anti-competitive behavior (Priority: 5/5): The episode details tactics such as pay-for-delay settlements, combination-product strategies, patent thickets, and lobbying to maintain monopolies and delay competitors. The role of philanthropy and nonprofit intervention (Priority: 4/5): John Arnold describes Arnold Ventures and Civica RX as attempts to address market failures by building nonprofit alternatives for certain generics and pushing policy change. Reforming incentives and oversight (Priority: 4/5): Both guests argue that patent-office incentives, legal standing, and oversight structures are misaligned and must be changed to make the system transparent and accountable. Value-based pricing and pricing reform (Priority: 4/5): Arnold outlines a framework for regulating monopoly drug prices using value-based pricing, reference pricing, and policies that reflect real therapeutic benefit and international benchmarks.

Key Arguments: U.S. drug prices are far above those in countries like Germany, Sweden, Canada, Australia, Europe, and Japan because companies exploit the patent system to extend monopoly control. The patent system was meant as a limited social contract, but it has been eroded by legal and lobbying tactics that allow companies to hold monopoly power long after the original patent term. Patent offices grant too many patents and are structurally incentivized toward approval rather than rejection, which encourages patent thickets and weak competition. Pharma’s argument that high prices are needed to fund innovation is overstated; most industry revenue comes from older repurposed products rather than new breakthroughs. Pay-for-delay settlements and related tactics function like anti-competitive conduct and should be treated more aggressively by antitrust regulators. A nonprofit generic manufacturer can stabilize supply and lower prices for hard-to-source drugs, proving that market failures can be corrected outside the traditional for-profit model. A more modern pharmaceutical policy framework should combine anti-competitive enforcement, incentive reform, and some form of price/value regulation for monopoly drugs.

Data Points: Americans affected by drug-cost hardship: 34 million - Reported as having lost a family member or friend in the last five years because of high drug costs. People who skipped prescriptions due to cost: 1 in 4 Americans - One-quarter reported they or a family member did not fill a prescription in the past year because of cost. Average price abroad relative to U.S.: 56% - People in other countries spend about 56% of what Americans spend on the same drug. Average patents per top drug: 125 patents - IMAC’s report found that the top 12 bestselling drugs in America had, on average, 125 patents filed around them. Statutory monopoly period: 20 years - The legal patent term that should limit monopoly protection before competition begins. Extended monopoly period: Nearly 40 years or longer - Result of patent stacking and other legal tactics used by drug firms. Price increase since 2012: 68% - Average increase for the 12 bestselling drugs since 2012, more than seven times inflation. Humira patent filings: 247 patents filed; 136 granted - AbbVie’s patent strategy on America’s top-selling drug, Humira. Humira price impact: At least $14 billion extra - Estimated additional cost to Americans compared with other countries. Humira U.S. spending: About $13 billion a year - Annual American spending on Humira cited in the discussion. Herceptin course cost: About $70,000 per year - Approximate annual cost for a breast cancer treatment course. Herceptin monopoly extension attempt: Until 2033 / about 48 years - Roche’s attempted prolongation of monopoly control through patenting and settlements. Competitive price reduction for Herceptin biosimilars: 15% cheaper - Two U.S. competitors entered and undercut the original product modestly. HIV drug litigation impact: Up to 87% price reduction - IMAC’s global litigation on unjust HIV drug patents brought prices down sharply. Health-system savings from HIV cases: Half a billion dollars - Savings from reduced prices on three drugs alone. Pharma revenue from older drugs: 89% - Industry revenue largely comes from older repurposed products rather than new launches (2017 research). Revenue from new products: 11% - Share of revenue from newly launched products or those launched in the last five years. Pharmaceutical spending share of health care: 15% to 18% - John Arnold’s estimate of pharma’s share of total U.S. health-care spending. Health-care spending share of GDP: About 18% - Overall U.S. health-care spending as a share of GDP. Total U.S. health care spending: About $3.5 trillion - Round-number estimate given by John Arnold. Annual U.S. pharma spending: About $600 billion - Approximate current spending on pharmaceuticals in the U.S. Projected CBO savings from Medicare negotiation: About $75 billion a year - Estimated savings once a House bill kicks in in the middle of the next decade. Projected global pharma revenues: About $1.5 trillion a year - Expected middle-of-next-decade industry revenues used as comparison. Civica RX pricing: 20% to 25% of market price - Some hospital drugs are being offered at a fraction of prevailing prices through the nonprofit generic effort.

Pivotal Quotes: "We have a completely broken market when it comes to prescription drugs." — Nick Hanauer: Opening framing of the episode’s central thesis on U.S. pharma pricing. "The pharmaceutical companies, on average, had filed 125 patents for these drugs. So this allows companies to go from 20 years of monopoly protection... to nearly 40 years or even longer." — Prithi Krishthal: Explaining patent walls and how patent stacking extends exclusivity. "We need to raise the bar and not hand out so many patents except for truly breakthrough inventions." — Prithi Krishthal: Discussing the need for patent-system reform and stronger oversight.

Implications: Listeners are being urged to see drug pricing as a structural policy failure, not just a health-care billing issue. The episode suggests reform will require patent, antitrust, and pricing changes plus public pressure to curb monopoly abuse and lower costs.